A panel of Food and Drug Administration advisers will vote Tuesday on whether to authorize the Pfizer-BioNTech COVID-19 vaccine for use in children 5 to 11. Once the advisory committee has approved the vaccine, three steps remain before it would be available to children: The FDA will have to sign off, an independent CDC advisory panel will review the data, and then the CDC director would have to sign off. Children are far less likely than adults to be hospitalized with COVID-19 or suffer long-term consequences from the disease, putting a higher burden on the vaccines to prove safe and effective to justify their risks.
» Subscribe to USA TODAY:
» Watch more on this and other topics from USA TODAY:
» USA TODAY delivers current local and national news, sports, entertainment, finance, technology, and more through award-winning journalism, photos, videos and VR.